deltatrials
Terminated PHASE2/PHASE3 NCT00978354

Furosemide in Early Acute Kidney Injury

A Phase II Randomized Blinded Controlled Trial of the Effect of furoSemide in Critically Ill Patients With eARly Acute Kidney Injury (The SPARK Study)

Sponsor: Austin Hospital, Melbourne Australia

Conditions Acute Renal Failure
Interventions Furosemide Normal Saline
Updated 6 times since 2017 Last updated: Sep 28, 2015 Started: Sep 30, 2009 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This PHASE2/PHASE3 trial investigates Acute Renal Failure and is currently terminated or withdrawn. Austin Hospital, Melbourne Australia leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2_PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2_PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2_PHASE3

    First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Austin Hospital, Melbourne Australia
  • Princess Alexandra Hospital, Brisbane, Australia
  • University of Alberta
Data source: University of Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Brisbane, Australia
  • • Edmonton, Canada
  • • Melbourne, Australia
  • • Québec, Canada